Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - The OVAR-IMRT-02 Study
2011

Study on Whole Abdominal Radiotherapy for Ovarian Cancer

Sample size: 37 publication 10 minutes Evidence: moderate

Author Information

Author(s): Rochet Nathalie, Kieser Meinhard, Sterzing Florian, Krause Sonja, Lindel Katja, Harms Wolfgang, Eichbaum Michael H, Schneeweiss Andreas, Sohn Christof, Debus Juergen

Primary Institution: University of Heidelberg

Hypothesis

Can intensity-modulated whole abdominal radiotherapy improve tolerability in patients with advanced ovarian cancer after chemotherapy?

Conclusion

The study aims to evaluate the tolerability and toxicity of intensity-modulated whole abdominal radiotherapy in patients with advanced ovarian cancer.

Supporting Evidence

  • Ovarian cancer has a poor prognosis despite aggressive treatment.
  • Intensity-modulated radiotherapy may reduce toxicity compared to conventional methods.
  • The study aims to demonstrate good tolerability of the new treatment approach.

Takeaway

This study is testing a new type of radiation therapy for women with advanced ovarian cancer to see if it is easier for them to handle than older methods.

Methodology

This is a single-center, one-arm phase II trial treating 37 patients with intensity-modulated whole abdominal radiotherapy.

Potential Biases

Potential bias due to the single-arm design and lack of control group.

Limitations

The study is limited to a single center and may not be generalizable to all populations.

Participant Demographics

Patients with advanced ovarian cancer stage FIGO III, optimally debulked, and in complete remission after chemotherapy.

Statistical Information

P-Value

0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-11-41

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication